RxDoctor Payments Data

Michael Ptasnik

Cardiovascular Disease · Lakewood, CONPI 1952307829

Payments from drug & device makers

$6,187in general payments, 2019–2025

Across 179 payments — averaging $34.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$1K
  • Medtronic$970
  • Amgen$694
  • Abiomed$340
  • E.r. Squibb & Sons, L.L.C.$323
  • Sanofi-aventis U.S. LLC$286
  • plus $3K from 33 others

What the payments were for

  • Consulting fees$170%
  • Food & beverage$5,80894%
  • Education$1392%
  • Other$2244%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,187 in reported general payments places this provider in the 70th percentile of 276 cardiovascular disease providers in Colorado.

See all cardiovascular disease providers in Colorado

Medicare billing

Part B allowed, 2024
$122,848
Medicare patients
295
Services billed
1,544

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban462$536,541
XareltoRivaroxaban35$38,516
Repatha SureclickEvolocumab49$36,194
LivaloPitavastatin Calcium23$25,589
EntrestoSacubitril/Valsartan21$16,753
FarxigaDapagliflozin Propanediol14$15,819
JardianceEmpagliflozin17$11,775
BystolicNebivolol Hcl18$9,791
Nebivolol Hcl101$7,029
Atorvastatin Calcium545$6,179
Metoprolol Succinate354$4,506
Midodrine Hcl16$4,481
Rosuvastatin Calcium201$4,195
Pitavastatin Calcium11$4,192
Losartan Potassium381$4,035

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$178$536,541462 claims
Johnson & JohnsonXarelto$66$38,51635 claims
Kowa Pharmaceuticals America, Inc.Livalo, Bystolic$97$35,38041 claims
NovartisEntresto$105$16,75321 claims
AstraZenecaFarxiga$22$15,81914 claims
Boehringer IngelheimJardiance$78$11,77517 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 276 cardiovascular disease providers in Colorado.

Other cardiovascular disease in Lakewood

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →